← Human Trials & Peer-Reviewed Studies
Omega-3 fatty acid supplement skin cancer prophylaxis in lung transplant recipients: A randomized, controlled pilot trial.
Plain-language guide to PMID 30352778 (2019): double-blind randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 30352778
- Journal
- The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Miura K et al. (8 authors)
- DOI
- 10.1016/j.healun.2018.09.009
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Copper (Supplement).
Lung transplant recipients (LTRs) are at very high risk of skin cancer.
Who Took Part
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
LTRs aged 18+ years, at least 1 year post-transplant, were recruited from the outpatient clinic of The Prince Charles Hospital, Brisbane.
Primary outcomes were rates of recruitment, retention, adherence (assessed by plasma omega-3 FA), and safety.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and pilot.
Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.
As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.
It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.
Secondary outcomes were incident skin cancers.
What Was Measured
PubMed files the paper under topics including Dietary Supplements, Fatty Acids, Omega-3, Lung Transplantation, Medication Adherence, Pilot Projects, Skin Neoplasms and Transplant Recipients.
The authors tagged it with the keywords Fish oil, Omega-3 fatty acids, Organ transplantation and Randomized placebo controlled.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2019 (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation), a journal based in United States.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.